The DOI matches its Crossref record; 316 of the 316 references it cites were found in a registry or an index.
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Open accessAbstract
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
G PROTEINS: TRANSDUCERS OF RECEPTOR-GENERATED SIGNALS
Gilman, A. G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003151 · Cited by 6,381
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Liquid-Liquid Phase Separation in Biology
Hyman, A. A., Weber, C. A., & Jülicher, F. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013325 · Cited by 3,155
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,701
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Elucidation of a universal size-control mechanism in Drosophila and mammals
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., & Pan, D. (2007) · Cell · doi:10.1016/j.cell.2007.07.019 · Cited by 2,370
Transcription factors: from enhancer binding to developmental control
Spitz, F., & Furlong, E. E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3207 · Cited by 2,227
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Cancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
A Phase Separation Model for Transcriptional Control
Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K., & Sharp, P. A. (2017) · Cell · doi:10.1016/j.cell.2017.02.007 · Cited by 1,753
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Emerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
GAL4-VP16 is an unusually potent transcriptional activator
Sadowski, I., Ma, J., Triezenberg, S., & Ptashne, M. (1988) · Nature · doi:10.1038/335563a0 · Cited by 1,333
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Pajtler, K. W., Witt, H., Sill, M., Jones, D. T. W., Hovestadt, V., Kratochwil, F., Wani, K., Tatevossian, R., Punchihewa, C., Johann, P., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.002 · Cited by 1,225
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., & Piccolo, S. (2015) · Nature Cell Biology · doi:10.1038/ncb3216 · Cited by 1,219
Tissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145
Self-citationThe Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Wu, S., Huang, J., Dong, J., & Pan, D. (2003) · Cell · doi:10.1016/s0092-8674(03)00549-x · Cited by 1,098
Nishioka, N., Inoue, K.-I., Adachi, K., Kiyonari, H., Ota, M., Ralston, A., Yabuta, N., Hirahara, S., Stephenson, R. O., Ogonuki, N., et al. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.02.003 · Cited by 1,078
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Justice, R. W., Zilian, O., Woods, D. F., Noll, M., & Bryant, P. J. (1995) · Genes & Development · doi:10.1101/gad.9.5.534 · Cited by 977
The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis
Harvey, K. F., Pfleger, C. M., & Hariharan, I. K. (2003) · Cell · doi:10.1016/s0092-8674(03)00557-9 · Cited by 976
The metabolism of cancer cells during metastasis
Bergers, G., & Fendt, S.-M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00320-2 · Cited by 950
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Statins: mechanism of action and effects
Stancu, C., & Sima, A. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00172.x · Cited by 911
Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 amplicon
Overholtzer, M., Zhang, J., Smolen, G. A., Muir, B., Li, W., Sgroi, D. C., Deng, C.-X., Brugge, J. S., & Haber, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605579103 · Cited by 885
The Hippo Signaling Pathway in Development and Disease
Zheng, Y., & Pan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.003 · Cited by 867
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Xu, T., Wang, W., Zhang, S., Stewart, R. A., & Yu, W. (1995) · Development · doi:10.1242/dev.121.4.1053 · Cited by 799
Metabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776
β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., Zack, T. I., Wang, X., Tsherniak, A., Schinzel, A. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.026 · Cited by 757
AMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 754
Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway
Udan, R. S., Kango-Singh, M., Nolo, R., Tao, C., & Halder, G. (2003) · Nature Cell Biology · doi:10.1038/ncb1050 · Cited by 747
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Ellis, P., Fagan, B. M., Magness, S. T., Hutton, S., Taranova, O., Hayashi, S., McMahon, A., Rao, M., & Pevny, L. (2004) · Developmental Neuroscience · doi:10.1159/000082134 · Cited by 742
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
Lamar, J. M., Stern, P., Liu, H., Schindler, J. W., Jiang, Z.-G., & Hynes, R. O. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212021109 · Cited by 654
A gp130–Src–YAP module links inflammation to epithelial regeneration
Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T., et al. (2015) · Nature · doi:10.1038/nature14228 · Cited by 633
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer
Jiao, S., Wang, H., Shi, Z., Dong, A., Zhang, W., Song, X., He, F., Wang, Y., Zhang, Z., Wang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.010 · Cited by 602
Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
Antonescu, C. R., Le Loarer, F., Mosquera, J., Sboner, A., Zhang, L., Chen, C., Chen, H., Pathan, N., Krausz, T., Dickson, B. C., et al. (2013) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22073 · Cited by 597
YAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
Self-citationFeng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer
O'Hayre, M., Vázquez-Prado, J., Kufareva, I., Stawiski, E. W., Handel, T. M., Seshagiri, S., & Gutkind, J. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3521 · Cited by 559
A WW domain-containing Yes-associated protein (YAP) is a novel transcriptional co-activator
Yagi, R., Chen, L.-F., Shigesada, K., Murakami, Y., & Ito, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.9.2551 · Cited by 558
Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D.-S., & Guan, K.-L. (2015) · Nature Cell Biology · doi:10.1038/ncb3111 · Cited by 557
Self-citationTargeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
Expression of Yes-associated protein in common solid tumors
Steinhardt, A. A., Gayyed, M. F., Klein, A. P., Dong, J., Maitra, A., Pan, D., Montgomery, E. A., & Anders, R. A. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.04.012 · Cited by 552
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway
Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H. W., Mo, J.-S., Lu, W., Lu, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9357 · Cited by 530
Self-citationSynergistic activation by the glutamine-rich domains of human transcription factor Sp1
Courey, A. J., Holtzman, D. A., Jackson, S. P., & Tjian, R. (1989) · Cell · doi:10.1016/0092-8674(89)90606-5 · Cited by 524
Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., & Pan, D. (2013) · Cell · doi:10.1016/j.cell.2013.08.025 · Cited by 504
Oncogenic KRAS signalling in pancreatic cancer
Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.215 · Cited by 504
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.001 · Cited by 500
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Hnisz, D., Schuijers, J., Lin, C. Y., Weintraub, A. S., Abraham, B. J., Lee, T. I., Bradner, J. E., & Young, R. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.014 · Cited by 476
Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis
Wang, K.-C., Yeh, Y.-T., Nguyen, P., Limqueco, E., Lopez, J., Thorossian, S., Guan, K.-L., Li, Y.-S. J., & Chien, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613121113 · Cited by 471
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
Bethune, G. C., Bethune, D. C. G., Ridgway, N. D., & Xu, Z. (2010) · Europe PMC (PubMed Central) · Cited by 469
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Yu, F.-X., Luo, J., Mo, J.-S., Liu, G., Kim, Y. C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.017 · Cited by 463
Komuro, A., Nagai, M., Navin, N. E., & Sudol, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305597200 · Cited by 456
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Moroishi, T., Hayashi, T., Pan, W.-W., Fujita, Y., Holt, M. V., Qin, J., Carson, D. A., & Guan, K.-L. (2016) · Cell · doi:10.1016/j.cell.2016.11.005 · Cited by 431
Morin-Kensicki, E. M., Boone, B. N., Howell, M., Stonebraker, J. R., Teed, J., Alb, J. G., Magnuson, T. R., O'Neal, W., & Milgram, S. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.77-87.2006 · Cited by 429
AMPK β Subunit Targets Metabolic Stress Sensing to Glycogen
Polekhina, G., Gupta, A., Michell, B. J., van Denderen, B., Murthy, S., Feil, S. C., Jennings, I. G., Campbell, D. J., Witters, L. A., Parker, M. W., et al. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00292-6 · Cited by 423
14-3-3 proteins: regulation of subcellular localization by molecular interference
MUSLIN, A. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00131-5 · Cited by 417
Phase separation of YAP reorganizes genome topology for long-term YAP target gene expression
Cai, D., Feliciano, D., Dong, P., Flores, E., Gruebele, M., Porat-Shliom, N., Sukenik, S., Liu, Z., & Lippincott-Schwartz, J. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0433-z · Cited by 416
Aerobic glycolysis tunes YAP/TAZ transcriptional activity
Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490379 · Cited by 414
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
Kibra Is a Regulator of the Salvador/Warts/Hippo Signaling Network
Genevet, A., Wehr, M. C., Brain, R., Thompson, B. J., & Tapon, N. (2010) · Developmental Cell · doi:10.1016/j.devcel.2009.12.011 · Cited by 402
Structural insights into the YAP and TEAD complex
Li, Z., Zhao, B., Wang, P., Chen, F., Dong, Z., Yang, H., Guan, K.-L., & Xu, Y. (2010) · Genes & Development · doi:10.1101/gad.1865810 · Cited by 401
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
Tanas, M. R., Sboner, A., Oliveira, A. M., Erickson-Johnson, M. R., Hespelt, J., Hanwright, P. J., Flanagan, J., Luo, Y., Fenwick, K., Natrajan, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002409 · Cited by 401
Zaidi, S. K., Sullivan, A. J., Medina, R., Ito, Y., van Wijnen, A. J., Stein, J. L., Lian, J. B., & Stein, G. S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600073 · Cited by 398
The WW domain: a signalling site in dystrophin?
Bork, P., & Sudol, M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90053-1 · Cited by 388
McClatchey, A. I., Saotome, I., Mercer, K., Crowley, D., Gusella, J. F., Bronson, R. T., & Jacks, T. (1998) · Genes & Development · doi:10.1101/gad.12.8.1121 · Cited by 388
Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration
Fan, F., He, Z., Kong, L.-L., Chen, Q., Yuan, Q., Zhang, S., Ye, J., Liu, H., Sun, X., Geng, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2304 · Cited by 382
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma
Bhat, K. P. L., Salazar, K. L., Balasubramaniyan, V., Wani, K., Heathcock, L., Hollingsworth, F., James, J. D., Gumin, J., Diefes, K. L., Kim, S. H., et al. (2011) · Genes & Development · doi:10.1101/gad.176800.111 · Cited by 377
Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice
Adam, R. C., Yang, H., Rockowitz, S., Larsen, S. B., Nikolova, M., Oristian, D. S., Polak, L., Kadaja, M., Asare, A., Zheng, D., et al. (2015) · Nature · doi:10.1038/nature14289 · Cited by 375
Montaner, S., Sodhi, A., Molinolo, A., Bugge, T. H., Sawai, E. T., He, Y., Li, Y., Ray, P. E., & Gutkind, J. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00237-4 · Cited by 373
Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression
Lu, Y., Wu, T., Gutman, O., Lu, H., Zhou, Q., Henis, Y. I., & Luo, K. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0485-0 · Cited by 371
A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis
Moroishi, T., Park, H. W., Qin, B., Chen, Q., Meng, Z., Plouffe, S. W., Taniguchi, K., Yu, F.-X., Karin, M., Pan, D., et al. (2015) · Genes & Development · doi:10.1101/gad.262816.115 · Cited by 369
Mst2 and Lats Kinases Regulate Apoptotic Function of Yes Kinase-associated Protein (YAP)
Oka, T., Mazack, V., & Sudol, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804380200 · Cited by 367
Lipid metabolism in cancer cells under metabolic stress
Munir, R., Lisec, J., Swinnen, J. V., & Zaidi, N. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0451-4 · Cited by 365
Bianchi, A. B., Mitsunaga, S. I., Cheng, J. Q., Klein, W. M., Jhanwar, S. C., Seizinger, B., Kley, N., Klein-Szanto, A. J., & Testa, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.10854 · Cited by 360
Strano, S., Monti, O., Pediconi, N., Baccarini, A., Fontemaggi, G., Lapi, E., Mantovani, F., Damalas, A., Citro, G., Sacchi, A., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.008 · Cited by 360
Levy, D., Adamovich, Y., Reuven, N., & Shaul, Y. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.022 · Cited by 347
Pajtler, K. W., Mack, S. C., Ramaswamy, V., Smith, C. A., Witt, H., Smith, A., Hansford, J. R., von Hoff, K., Wright, K. D., Hwang, E., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1643-0 · Cited by 337
Yes-associated protein (YAP) functions as a tumor suppressor in breast
Yuan, M., Tomlinson, V, Lara, R., Holliday, D., Chelala, C., Harada, T., Gangeswaran, R., Manson-Bishop, C., Smith, P., Danovi, S. A., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.108 · Cited by 335
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
Lallemand, D., Curto, M., Saotome, I., Giovannini, M., & McClatchey, A. I. (2003) · Genes & Development · doi:10.1101/gad.1054603 · Cited by 324
DeRan, M., Yang, J., Shen, C.-H., Peters, E. C., Fitamant, J., Chan, P., Hsieh, M., Zhu, S., Asara, J. M., Zheng, B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.036 · Cited by 316
Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319190110 · Cited by 316
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313
Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
Cottini, F., Hideshima, T., Xu, C., Sattler, M., Dori, M., Agnelli, L., ten Hacken, E., Bertilaccio, M. T., Antonini, E., Neri, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3562 · Cited by 309
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
Janse van Rensburg, H. J., Azad, T., Ling, M., Hao, Y., Snetsinger, B., Khanal, P., Minassian, L. M., Graham, C. H., Rauh, M. J., & Yang, X. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3139 · Cited by 306
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Zanconato, F., Battilana, G., Forcato, M., Filippi, L., Azzolin, L., Manfrin, A., Quaranta, E., Di Biagio, D., Sigismondo, G., Guzzardo, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0158-8 · Cited by 306
Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer
(1995) · Lung Cancer · doi:10.1016/0169-5002(95)90162-0 · Cited by 296
Extracellular vesicles in the tumor microenvironment: old stories, but new tales
Han, L., Lam, E. W.-F., & Sun, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0980-8 · Cited by 294
Single tumor-initiating cells evade immune clearance by recruiting type II macrophages
Guo, X., Zhao, Y., Yan, H., Yang, Y., Shen, S., Dai, X., Ji, X., Ji, F., Gong, X.-G., Li, L., et al. (2017) · Genes & Development · doi:10.1101/gad.294348.116 · Cited by 285
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Mizuno, T., Murakami, H., Fujii, M., Ishiguro, F., Tanaka, I., Kondo, Y., Akatsuka, S., Toyokuni, S., Yokoi, K., Osada, H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.5 · Cited by 279
The Hippo Pathway, YAP/TAZ, and the Plasma Membrane
Rausch, V., & Hansen, C. G. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.10.005 · Cited by 279
Self-citationCharacterization of Hippo Pathway Components by Gene Inactivation
Plouffe, S. W., Meng, Z., Lin, K. C., Lin, B., Hong, A. W., Chun, J. V., & Guan, K.-L. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.034 · Cited by 275
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Hall, C. A., Wang, R., Miao, J., Oliva, E., Shen, X., Wheeler, T., Hilsenbeck, S. G., Orsulic, S., & Goode, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1242 · Cited by 263
Noland, C. L., Gierke, S., Schnier, P. D., Murray, J., Sandoval, W. N., Sagolla, M., Dey, A., Hannoush, R. N., Fairbrother, W. J., & Cunningham, C. N. (2016) · Structure · doi:10.1016/j.str.2015.11.005 · Cited by 262
The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway
Furth, N., & Aylon, Y. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.99 · Cited by 260
Overexpression of RhoA, Rac1, and Cdc42 GTPases Is Associated with Progression in Testicular Cancer
Kamai, T., Yamanishi, T., Shirataki, H., Takagi, K., Asami, H., Ito, Y., & Yoshida, K.-I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0436-03 · Cited by 255
Plouffe, S. W., Lin, K. C., Moore, J. L., Tan, F. E., Ma, S., Ye, Z., Qiu, Y., Ren, B., & Guan, K.-L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002715 · Cited by 252
Structural basis of YAP recognition by TEAD4 in the Hippo pathway
Chen, L., Chan, S. W., Zhang, X., Walsh, M., Lim, C. J., Hong, W., & Song, H. (2010) · Genes & Development · doi:10.1101/gad.1865310 · Cited by 249
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Basu-Roy, U., Bayin, N. S., Rattanakorn, K., Han, E., Placantonakis, D. G., Mansukhani, A., & Basilico, C. (2015) · Nature Communications · doi:10.1038/ncomms7411 · Cited by 247
Identification of Serum-Derived Sphingosine-1-Phosphate as a Small Molecule Regulator of YAP
Miller, E., Yang, J., DeRan, M., Wu, C., Su, A. I., Bonamy, G. M. C., Liu, J., Peters, E. C., & Wu, X. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.005 · Cited by 246
Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245
Fishman, D. A., Stack, S., Ellerbroek, S. M., & Liu, Y. (2022) · PubMed · doi:10.7274/24738663 · Cited by 241
Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.009 · Cited by 237
Ribeiro, P. S., Josué, F., Wepf, A., Wehr, M. C., Rinner, O., Kelly, G., Tapon, N., & Gstaiger, M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.002 · Cited by 235
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma
Sekine, S., Kiyono, T., Ryo, E., Ogawa, R., Wakai, S., Ichikawa, H., Suzuki, K., Arai, S., Tsuta, K., Ishida, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126185 · Cited by 235
Tead and AP1 Coordinate Transcription and Motility
Liu, X., Li, H., Rajurkar, M., Li, Q., Cotton, J. L., Ou, J., Zhu, L. J., Goel, H. L., Mercurio, A. M., Park, J.-S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.104 · Cited by 234
Horiuchi, A., Imai, T., Wang, C., Ohira, S., Feng, Y., Nikaido, T., & Konishi, I. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000073128.16098.31 · Cited by 233
YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity
Ni, X., Tao, J., Barbi, J., Chen, Q., Park, B. V., Li, Z., Zhang, N., Lebid, A., Ramaswamy, A., Wei, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1124 · Cited by 231
Finicle, B. T., Jayashankar, V., & Edinger, A. L. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0048-x · Cited by 228
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels
Harmar, A. J., Hills, R. A., Rosser, E. M., Jones, M., Buneman, O. P., Dunbar, D. R., Greenhill, S. D., Hale, V. A., Sharman, J. L., Bonner, T. I., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn728 · Cited by 227
Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm.
Wang, C., Zhu, X., Feng, W., Yu, Y., Jeong, K., Guo, W., Lu, Y., & Mills, G. B. (2016) · Europe PMC (PubMed Central) · Cited by 225
Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice
Moya, I. M., Castaldo, S. A., Van den Mooter, L., Soheily, S., Sansores-Garcia, L., Jacobs, J., Mannaerts, I., Xie, J., Verboven, E., Hillen, H., et al. (2019) · Science · doi:10.1126/science.aaw9886 · Cited by 218
Di Micco, R., Fontanals-Cirera, B., Low, V., Ntziachristos, P., Yuen, S. K., Lovell, C. D., Dolgalev, I., Yonekubo, Y., Zhang, G., Rusinova, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.055 · Cited by 217
Oka, T., Remue, E., Meerschaert, K., Vanloo, B., Boucherie, C., Gfeller, D., Bader, G. D., Sidhu, S. S., Vandekerckhove, J., Gettemans, J., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100870 · Cited by 216
Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth
Cox, A. G., Hwang, K. L., Brown, K. K., Evason, K. J., Beltz, S., Tsomides, A., O’Connor, K., Galli, G. G., Yimlamai, D., Chhangawala, S., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3389 · Cited by 215
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 215
Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis
Griss, T., Vincent, E. E., Egnatchik, R., Chen, J., Ma, E. H., Faubert, B., Viollet, B., DeBerardinis, R. J., & Jones, R. G. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002309 · Cited by 213
Hansen, C. G., Ng, Y. L. D., Lam, W.-L. M., Plouffe, S. W., & Guan, K.-L. (2015) · Cell Research · doi:10.1038/cr.2015.140 · Cited by 212
Self-citationNUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
French, C. A. (2018) · Pathology International · doi:10.1111/pin.12727 · Cited by 210
McClatchey, A. I., Saotome, I., Ramesh, V, Gusella, J. F., & Jacks, T. (1997) · Genes & Development · doi:10.1101/gad.11.10.1253 · Cited by 207
Pobbati, A. V., Han, X., Hung, A. W., Weiguang, S., Huda, N., Chen, G.-Y., Kang, C., Chia, C. S. B., Luo, X., Hong, W., et al. (2015) · Structure · doi:10.1016/j.str.2015.09.009 · Cited by 206
The role of YAP/TAZ activity in cancer metabolic reprogramming
Zhang, X., Zhao, H., Li, Y., Xia, D., Yang, L., Ma, Y., & Li, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0882-1 · Cited by 206
Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila
Wei, X., Shimizu, T., & Lai, Z. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601630 · Cited by 205
A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis
Zadra, G., Photopoulos, C., Tyekucheva, S., Heidari, P., Weng, Q. P., Fedele, G., Liu, H., Scaglia, N., Priolo, C., Sicinska, E., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302734 · Cited by 204
Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation
Lin, K. C., Moroishi, T., Meng, Z., Jeong, H.-S., Plouffe, S. W., Sekido, Y., Han, J., Park, H. W., & Guan, K.-L. (2017) · Nature Cell Biology · doi:10.1038/ncb3581 · Cited by 204
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196
The genomic landscape of retinoblastoma: a review
Thériault, B. L., Dimaras, H., Gallie, B. L., & Corson, T. W. (2014) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12132 · Cited by 196
Zhang, H., Ramakrishnan, S. K., Triner, D., Centofanti, B., Maitra, D., Győrffy, B., Sebolt-Leopold, J. S., Dame, M. K., Varani, J., Brenner, D. E., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac5418 · Cited by 196
Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 196
In vivo analysis of Yorkie phosphorylation sites
Oh, H., & Irvine, K. D. (2009) · Oncogene · doi:10.1038/onc.2009.43 · Cited by 195
Bum-Erdene, K., Zhou, D., Gonzalez-Gutierrez, G., Ghozayel, M. K., Si, Y., Xu, D., Shannon, H. E., Bailey, B. J., Corson, T. W., Pollok, K. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.010 · Cited by 193
Zhao, B., Kim, J., Ye, X., Lai, Z.-C., & Guan, K.-L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2997 · Cited by 192
T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Houot, R., Schultz, L. M., Marabelle, A., & Kohrt, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0190 · Cited by 185
A basal-like breast cancer-specific role for SRF–IL6 in YAP-induced cancer stemness
Kim, T., Yang, S.-J., Hwang, D., Song, J., Kim, M., Kyum Kim, S., Kang, K., Ahn, J., Lee, D., Kim, M.-Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms10186 · Cited by 181
Li, P., Silvis, M. R., Honaker, Y., Lien, W.-H., Arron, S. T., & Vasioukhin, V. (2016) · Genes & Development · doi:10.1101/gad.274951.115 · Cited by 180
Imamura, F., Horai, T., Mukai, M., Shinkai, K., Sawada, M., & Akedo, H. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1651 · Cited by 180
Sadler, K. C., Amsterdam, A., Soroka, C., Boyer, J., & Hopkins, N. (2005) · Development · doi:10.1242/dev.01918 · Cited by 179
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
GPCRs: Emerging anti-cancer drug targets
Nieto Gutierrez, A., & McDonald, P. H. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2017.09.005 · Cited by 175
Pearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lu, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 175
Zhang, Z., Lin, Z., Zhou, Z., Shen, H. C., Yan, S. F., Mayweg, A. V., Xu, Z., Qin, N., Wong, J. C., Zhang, Z., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500160m · Cited by 174
Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors
Holden, J., & Cunningham, C. (2018) · Cancers · doi:10.3390/cancers10030081 · Cited by 173
Li, Z., Wang, Y., Zhu, Y., Yuan, C., Wang, D., Zhang, W., Qi, B., Qiu, J., Song, X., Ye, J., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.007 · Cited by 169
Xia, Y., Chang, T., Wang, Y., Liu, Y., Li, W., Li, M., & Fan, H.-Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091770 · Cited by 167
Haskins, J. W., Nguyen, D. X., & Stern, D. F. (2014) · Science Signaling · doi:10.1126/scisignal.2005770 · Cited by 167
The Evolutionary History of YAP and the Hippo/YAP Pathway
Hilman, D., & Gat, U. (2011) · Molecular Biology and Evolution · doi:10.1093/molbev/msr065 · Cited by 166
Lee, B. S., Park, D. I., Lee, D. H., Lee, J. E., Yeo, M.-K., Park, Y. H., Lim, D. S., Choi, W., Lee, D. H., Yoo, G., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.007 · Cited by 166
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
Cosset, É., Ilmjärv, S., Dutoit, V., Elliott, K., von Schalscha, T., Camargo, M. F., Reiss, A., Moroishi, T., Seguin, L., Gomez, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.016 · Cited by 166
Noto, A., De Vitis, C., Pisanu, M. E., Roscilli, G., Ricci, G., Catizone, A., Sorrentino, G., Chianese, G., Taglialatela-Scafati, O., Trisciuoglio, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.75 · Cited by 165
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma
Castellan, M., Guarnieri, A., Fujimura, A., Zanconato, F., Battilana, G., Panciera, T., Sladitschek, H. L., Contessotto, P., Citron, A., Grilli, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00150-z · Cited by 163
Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53
Timpson, P., McGhee, E. J., Morton, J. P., von Kriegsheim, A., Schwarz, J. P., Karim, S. A., Doyle, B., Quinn, J. A., Carragher, N. O., Edward, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2267 · Cited by 162
YAP and TAZ Are Not Identical Twins
Reggiani, F., Gobbi, G., Ciarrocchi, A., & Sancisi, V. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.08.012 · Cited by 162
Zhang, L., Yang, S., Chen, X., Stauffer, S., Yu, F., Lele, S. M., Fu, K., Datta, K., Palermo, N., Chen, Y., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00102-15 · Cited by 161
The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells
Cai, H., & Xu, Y. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-31 · Cited by 161
Holden, J. K., Crawford, J. J., Noland, C. L., Schmidt, S., Zbieg, J. R., Lacap, J. A., Zang, R., Miller, G. M., Zhang, Y., Beroza, P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107809 · Cited by 161
Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets
Rosenbaum, E., Jadeja, B., Xu, B., Zhang, L., Agaram, N. P., Travis, W., Singer, S., Tap, W. D., & Antonescu, C. R. (2020) · Modern Pathology · doi:10.1038/s41379-019-0368-8 · Cited by 158
YAP is a critical oncogene in human cholangiocarcinoma
Pei, T., Li, Y., Wang, J., Wang, H., Liang, Y., Shi, H., Sun, B., Yin, D., Sun, J., Song, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4043 · Cited by 154
Liquid–Liquid Phase Separation in ChromatinPreprint
Rippe, K. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040683 · Cited by 150
Modularity in the Hippo signaling pathway
Sudol, M., & Harvey, K. F. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.010 · Cited by 149
The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα
Britschgi, A., Duss, S., Kim, S., Couto, J. P., Brinkhaus, H., Koren, S., Silva, D. D., Mertz, K. D., Kaup, D., Varga, Z., et al. (2017) · Nature · doi:10.1038/nature20829 · Cited by 148
Andreiuolo, F. D. M., Varlet, P., Tauziède‐Espariat, A., Jünger, S. T., Dörner, E., Dreschmann, V., Kuchelmeister, K., Waha, A., Haberler, C., Slavc, I., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12659 · Cited by 147
Tang, Y., Fang, G., Guo, F., Zhang, H., Chen, X., An, L., Chen, M., Zhou, L., Wang, W., Ye, T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.019 · Cited by 146
Phenotypic analysis of extracellular vesicles: a review on the applications of fluorescence
Panagopoulou, M. S., Wark, A. W., Birch, D. J. S., & Gregory, C. D. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1710020 · Cited by 145
Yap and Taz regulate retinal pigment epithelial cell fate
Miesfeld, J. B., Gestri, G., Clark, B. S., Flinn, M. A., Poole, R. J., Bader, J. R., Besharse, J. C., Wilson, S. W., & Link, B. A. (2015) · Development · doi:10.1242/dev.119008 · Cited by 143
Diepenbruck, M., Waldmeier, L., Ivánek, R., Berninger, P., Arnold, P., van Nimwegen, E., & Christofori, G. (2014) · Journal of Cell Science · doi:10.1242/jcs.139865 · Cited by 140
A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma
Hiemer, S. E., Zhang, L., Kartha, V. K., Packer, T. S., Almershed, M., Noonan, V. L., Kukuruzinska, M. A., Bais, M. V., Monti, S., & Varelas, X. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0580 · Cited by 139
Fossdal, R. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh106 · Cited by 138
Hayashi, H., Higashi, T., Yokoyama, N., Kaida, T., Sakamoto, K., Fukushima, Y., Ishimoto, T., Kuroki, H., Nitta, H., Hashimoto, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0291 · Cited by 136
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Leal, A. S., Williams, C. R., Royce, D. B., Pioli, P. A., Sporn, M. B., & Liby, K. T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.021 · Cited by 135
Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growthPreprint
Koo, J. H., Plouffe, S. W., Meng, Z., Lee, D.-H., Yang, D., Lim, D., Wang, C., & Guan, K. (2019) · Genes & Development · doi:10.1101/gad.331546.119 · Cited by 133
Research works printed but not linked: 12
- Evans, 2009, Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II], Genet. Med., 11, 599, 10.1097/GIM.0b013e3181ac9a27 · doi:10.1097/gim.0b013e3181ac9a27
- Begnami, 2007, Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization, Hum. Pathol., 38, 1345, 10.1016/j.humpath.2007.01.027 · doi:10.1016/j.humpath.2007.01.027
- Yakirevich, 2020, NF2 mutation-driven renal cell carcinomas (RCC): a comprehensive genomic profiling (CGP) study, J. Clin. Oncol., 38, 726, 10.1200/JCO.2020.38.6_suppl.726 · doi:10.1200/jco.2020.38.6_suppl.726
- Zhao, 2007, Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control, Genes Dev., 21, 2747, 10.1101/gad.1602907 · DOI · Paper page
- Lee, 2016, Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements, Oncotarget, 7, 7480, 10.18632/oncotarget.7060 · doi:10.18632/oncotarget.7060
- Russell-Goldman, 2021, Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma, J. Cutan. Pathol., 48, 403, 10.1111/cup.13924 · doi:10.1111/cup.13924
- Nishimura, 2021, Cutaneous primary NUT carcinoma with BRD3-NUTM1 fusion, Am. J. Surg. Pathol., 45, 1582, 10.1097/PAS.0000000000001801 · doi:10.1097/pas.0000000000001801
- Pei, 2015, YAP is a critical oncogene in human cholangiocarcinoma, Oncotarget, 6, 17206, 10.18632/oncotarget.4043 · DOI
- Carter, 1994, Loss of heterozygosity at 11q22-q23 in breast cancer, Cancer Res., 54, 6270
- Messmer, 2001, Verteporfin for age-related macular degeneration, Ann. Pharmacother., 35, 1593, 10.1345/aph.10365 · doi:10.1345/aph.10365 · Paper page
- Taniguchi, 2015, A gp130-Src-YAP module links inflammation to epithelial regeneration, Nature, 519, 57, 10.1038/nature14228 · DOI · Paper page
- Whitehouse, 2005, Drugs to treat inflammation: a historical introduction, Curr. Med. Chem., 12, 2931, 10.2174/092986705774462879 · doi:10.2174/092986705774462879
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Metadata
- Authors
- Cunningham, R., & Hansen, C. G.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2022-02
- Volume
- 136
- Issue
- 3
- Pages
- 197-222
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W4210383344
- Cited by
- 326
- References
- 316
- FWCI
- 29.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.